Date published: 2025-12-4

1-800-457-3801

SCBT Portrait Logo
Seach Input

SUCLA2 Activators

SUCLA2 activators encompass a range of chemicals that facilitate the activation of the SUCLA2 protein, which is a subunit of the succinate-CoA ligase enzyme complex involved in the citric acid cycle, also known as the tricarboxylic acid (TCA) cycle or Krebs cycle. This protein plays a critical role in the conversion of succinyl-CoA to succinate, with the concurrent formation of ADP or GDP from ATP or GTP, respectively, thereby contributing to the cellular energy metabolism.

Direct activators of SUCLA2 interact with the protein in a manner that enhances its enzymatic activity. This could involve binding to the active site of the enzyme in such a way that it increases the affinity of SUCLA2 for its substrates, succinyl-CoA and nucleoside diphosphates (ADP/GDP). They might also induce a conformational change in the SUCLA2 protein or its complex that promotes a more efficient catalysis of the reaction it mediates. Furthermore, these activators could prevent inhibitory molecules from interacting with SUCLA2, thereby increasing its overall activity. On the other hand, indirect activators of SUCLA2 might work by modulating the levels of substrates available to the enzyme or by influencing the expression and stability of the SUCLA2 protein. They can enhance the synthesis of succinyl-CoA and ADP/GDP, making them more readily available to the SUCLA2 complex. Alternatively, these activators might also act by modifying the mitochondrial environment to favor the activity of the SUCLA2 complex or by influencing post-translational modifications that enhance the protein's stability and function.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Dichloroacetic acid

79-43-6sc-214877
sc-214877A
25 g
100 g
$60.00
$125.00
5
(0)

Dichloroacetate activates pyruvate dehydrogenase, enhancing the conversion of pyruvate to acetyl-CoA, which can lead to increased TCA cycle flux and potentially influence SUCLA2.

AICAR

2627-69-2sc-200659
sc-200659A
sc-200659B
50 mg
250 mg
1 g
$60.00
$270.00
$350.00
48
(2)

AICAR activates AMPK, which can enhance catabolic processes like the TCA cycle, potentially influencing SUCLA2.

Metformin-d6, Hydrochloride

1185166-01-1sc-218701
sc-218701A
sc-218701B
1 mg
5 mg
10 mg
$286.00
$806.00
$1510.00
1
(1)

Metformin activates AMPK, leading to an increased rate of catabolic processes, including the TCA cycle where SUCLA2 operates.

Sodium phenylbutyrate

1716-12-7sc-200652
sc-200652A
sc-200652B
sc-200652C
sc-200652D
1 g
10 g
100 g
1 kg
10 kg
$75.00
$163.00
$622.00
$4906.00
$32140.00
43
(1)

Sodium phenylbutyrate is a histone deacetylase inhibitor that can alter gene expression, potentially influencing SUCLA2.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

5-Azacytidine is a DNA methyltransferase inhibitor that can alter gene expression, potentially influencing SUCLA2.

Sodium Butyrate

156-54-7sc-202341
sc-202341B
sc-202341A
sc-202341C
250 mg
5 g
25 g
500 g
$30.00
$46.00
$82.00
$218.00
19
(3)

Sodium butyrate is a histone deacetylase inhibitor that can alter gene expression, potentially influencing SUCLA2.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 inhibits PI3K, leading to AMPK activation which can enhance catabolic processes like the TCA cycle, potentially influencing SUCLA2.

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

Staurosporine inhibits protein kinases, which can disrupt various signaling pathways and potentially influence SUCLA2 indirectly by altering cellular metabolism.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

Trichostatin A inhibits histone deacetylases, altering gene expression and potentially influencing SUCLA2.

Valproic Acid

99-66-1sc-213144
10 g
$85.00
9
(1)

Valproic acid is a histone deacetylase inhibitor that can alter gene expression, potentially influencing SUCLA2.